Supplementary Figure S1: Survival analysis based on FGFR1 gene status and FGFR1 protein expression level. (A) Kaplan–Meier plot of disease-free survival (DFS) of 52 patients with MPNST based on status of FGFR1 gene expression. (B) Kaplan–Meier plot of overall survival (OS) of 52 patients with MPNST based on status of FGFR1 gene expression. (C) Kaplan–Meier plot of DFS of 63 patients with MPNST based on level of FGFR1 protein expression. (D) Kaplan–Meier plot of DFS in the FGFR1-amplified group (14 cases) of MPNST patients based on FGFR1 protein expression. (E) Kaplan–Meier plot of DFS in the FGFR1-normal group (38 cases) of MPNST patients based on FGFR1 protein expression. (F) Kaplan–Meier plot of OS in the FGFR1-normal group (38 cases) of MPNST patients based on FGFR1 protein expression.
Supplementary Figure S2: Survival analysis based on FGFR2, FGFR1 and FGFR2, and FGFR4 protein expression levels. (A) Kaplan–Meier plot of disease-free survival (DFS) of 61 patients with MPNST based on level of FGFR2 protein expression. (B) Kaplan–Meier plot of overall survival (OS) of 61 patients with MPNST based on level of FGFR2 protein expression. (C) DFS of 59 MPNST patients based on FGFR1 and FGFR2 protein expression status. (D) FGFR3 protein expression in KMS-11 cells (positive control) (40×). (E) FGFR3 protein expression in a representative human MPNST tissue sample (40×). (F) Kaplan–Meier plot of OS of 62 patients with MPNST based on level of FGFR4 protein expression.